As the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT),
Lutathera® was approved by the EMA in 2017 and the FDA in 2018 for the treatment of …

Background External cooling of the salivary glands is advised to prevent xerostomia in
lutetium-177-PSMA treatment for advanced prostate cancer. Since evidence addressing this …

Introduction Computational models yield valuable insights into biological interactions not
fully elucidated by experimental approaches. This study investigates an innovative …

Recent years have seen the start of treatment of metastatic castration-resistant prostate
cancer with prostate-specific membrane antigen (PSMA)–targeted radioligand therapy …

Because of different physical properties, the β-emitters 177Lu and 90Y offer specific
radiologic–biologic advantages in dedicated clinical situations. Our objective was to …

Background The aim of this study was to evaluate the predictive power of the absorbed dose
to kidneys after the first course of treatment with [177 Lu]-DOTA-TATE for neuroendocrine …

The study aims to evaluate the radiation safety conditions by detecting the patient's urine
excretion rate, calculating the effective half-life, and determining the retention of 177Lu …

Cardiovascular nuclear medicine (NM) imaging examinations expose patients to extremely
high absorbed doses of ionizing radiation, which necessitates extensive efforts to reduce the …

To date, myocardial perfusion (MP) has been utilized to assess the adequacy of blood flow
to the myocardium in order to determine the ischemic heart diseases. With the advent of …

Purpose 177Lu-DOTATATE therapy is an effective treatment strategy for the treatment of
neuroendocrine tumours. However, it could cause severe side effects in major critical …